Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning, and can be disabling.
PAGE Running head SCHIZOPHRENIA 1SchizophreniaVernessa.docxkarlhennesey
PAGE
Running head: SCHIZOPHRENIA
1
Schizophrenia
Vernessa Combs
PSY350: Physiological Psychology
December 10, 2019
Schizophrenia
The topic selected was schizophrenia. This is a severe and chronic mental disorder affecting the way humans think, feel and behave. Although this mental disorder is not very common, it has disabling symptoms.
Schizophrenia has continuously been viewed as a disorder that occurs in neurodevelopment. It is associated with a microdeletion syndrome of a chromosome. Neurons migrate to the pial surface from the brain's ventricular zone. "Migration of the neuron cell body is mediated via microtubule-based transport organized by the centrosome. First, the centrosome moves up the microtubule, followed by the nucleus and the cell body” (Pearlson, 2015). Neuronal migrations are reportedly caused by Reelin.
The etiology of schizophrenia is unknown, however, several risk factors have been associated with its development. These include environmental and genetic factors. Genetic factors are, however, insufficient to account for the development of the disease. They must be accompanied by other factors for the disease to develop. "Because the concordance rate for monozygotic twins only approaches 50%, genetic makeup alone is not sufficient for the development of schizophrenia, and non-genetic or sporadic forms of the disorder must exist” (Miyamoto et al, 2013).
Environmental factors that play an important role in the etiology of schizophrenia include obstetric complications such as hypoxia, preeclampsia, and premature birth. Other environmental factors include maternal viral infections and stress occurring in neurodevelopment. Stress during neurodevelopment may be caused by other factors such as microbial infections.
The pathology of schizophrenia includes the transcriptional dysregulation at the cerebral cortex and chromosomal conformations. “Anatomic, neurotransmitter and immune system abnormalities have been implicated in the pathophysiology of schizophrenia” (Miyamoto et al, 2013). Differences have been observed in the brains of people with schizophrenia compared to the brains of people without the disease in neuroimaging studies. The medial temporal areas of the brain have a decreased volume while the ventricles are larger. Structural abnormalities such as volume reductions and ventricular enlargements have been associated with the disease.
The dopaminergic system abnormalities are also associated with schizophrenia. The immune system is also disturbed in people with the disease. “Overactivation of the immune system (eg, from prenatal infection or postnatal stress) may result in overexpression of inflammatory cytokines and subsequent alteration of brain structure and function” (Nuckols et al, 2013). Anatomic abnormalities may also be observed in the hippocampus.
In the prefrontal cortex, there has been a reported increase in neuronal density. One of the areas of the prefrontal cortex, area 9, has been found to h ...
Summary Report: "Mental Health Throughout Life"
Herrenhausen Conference on Mental Illnesses, Hanover, April 3-5, 2013
Mechanisms of vulnerability for mental illnesses over lifetime were the focus of the Volkswagen Foundation’s second Herrenhausen Conference. Concentrating on particularly sensitive and susceptible phases of mental development, renowned experts shared their latest research and insights into risk for and resilience against mental illnesses. Building on this material, in a concluding Session new approaches for improving mental health and treating mental disorders were highlighted.
Folks with schizophrenia may hear voices that are not there. Some may be convinced that other folks are reading their thoughts, controlling how they think, or plotting against them. This can distress patients severely and persistently, making them withdrawn and frantic.
READINGS The following two articles show breathtaking advances.docxcatheryncouper
READINGS
The following two articles show breathtaking advances in the ability to detect whether a person will suffer from a particular genetic disease. The first article contains references to all three types of evidence discussed in this chapter. Compare the language used to depict direct experimentation, after-the-fact evidence, and values questions.
Predictive Probes
by Jerry E. Bishop
Several years ago, Nancy Wexler’s mother died of Huntington’s disease, a hereditary and always-fatal affliction that strikes in midlife. Since then, Ms. Wexler, the 38-year-old president of the Hereditary Diseases Foundation in Santa Monica, Calif., has lived with the uncertainty of whether she, too, inherited the deadly gene.
That uncertainty may soon be resolved. A few months ago, scientists announced they were on the verge of completing a new test to detect the gene for Huntington’s disease (formerly called Huntington’s chorea). But deciding whether to submit herself to the test is an anguishing choice for Ms. Wexler. “If I came out lucky, taking the test would be terrific, of course,” she says. “But if I came out unlucky, well …”
Her dilemma is an extreme example of the kind thousands of Americans will face in the not-too-distant future as scientists learn how to pinpoint genes that cause or predispose a person to a future illness.
The test to detect the Huntington’s disease gene should be ready within one to two years. Researchers already have detected some of the genes that can lead to premature heart attacks and, in the near future, hope to spot those that could predispose a person to breast or colon cancer. Eventually, scientists believe they will be able to detect genes leading to diabetes, depression, schizophrenia and the premature senility called Alzheimer’s disease.
“Extraordinary Power.”
“This new technology has an extraordinary power to predict any disease where there is any kind of genetic influence,” Ms. Wexler says. “Instead of looking in a crystal ball to see your future, you’ll look in your genes.”
Doctors long have been able to crudely predict a person’s future illness. By studying disease patterns, for example, they can say that heavy cigarette smokers have 10 times the risk of developing lung cancer as nonsmokers and that middle-aged men with high blood cholesterol levels have higher-than-normal risk of heart attacks. Geneticists also look at family medical pedigrees to determine the chances of children inheriting any of the 3,000 known genetic disorders.
But such predictions are similar to casino odds. Doctors can’t predict which smokers will actually develop lung cancer, which individual will have a premature heart attack or which child actually inherited a defective gene.
Genetic probes, however, will change predictive medicine. The probes are synthetic versions of genes that cause disease. Tossed into a test tube with a small sample of a person’s own genetic material—his DNA—the probes cling to and identify their n ...
Predictive Probes (Art. 1)by Jerry E. BishopSeveral years .docxChantellPantoja184
Predictive Probes (Art. 1)
by Jerry E. Bishop
Several years ago, Nancy Wexler’s mother died of Huntington’s disease, a hereditary and always-fatal affliction that strikes in midlife. Since then, Ms. Wexler, the 38-year-old president of the Hereditary Diseases Foundation in Santa Monica, Calif., has lived with the uncertainty of whether she, too, inherited the deadly gene.
That uncertainty may soon be resolved. A few months ago, scientists announced they were on the verge of completing a new test to detect the gene for Huntington’s disease (formerly called Huntington’s chorea). But deciding whether to submit herself to the test is an anguishing choice for Ms. Wexler. “If I came out lucky, taking the test would be terrific, of course,” she says. “But if I came out unlucky, well …”
Her dilemma is an extreme example of the kind thousands of Americans will face in the not-too-distant future as scientists learn how to pinpoint genes that cause or predispose a person to a future illness.
The test to detect the Huntington’s disease gene should be ready within one to two years. Researchers already have detected some of the genes that can lead to premature heart attacks and, in the near future, hope to spot those that could predispose a person to breast or colon cancer. Eventually, scientists believe they will be able to detect genes leading to diabetes, depression, schizophrenia and the premature senility called Alzheimer’s disease.
“This new technology has an extraordinary power to predict any disease where there is any kind of genetic influence,” Ms. Wexler says. “Instead of looking in a crystal ball to see your future, you’ll look in your genes.”
Doctors long have been able to crudely predict a person’s future illness. By studying disease patterns, for example, they can say that heavy cigarette smokers have 10 times the risk of developing lung cancer as nonsmokers and that middle-aged men with high blood cholesterol levels have higher-than-normal risk of heart attacks. Geneticists also look at family medical pedigrees to determine the chances of children inheriting any of the 3,000 known genetic disorders.
But such predictions are similar to casino odds. Doctors can’t predict which smokers will actually develop lung cancer, which individual will have a premature heart attack or which child actually inherited a defective gene.
Genetic probes, however, will change predictive medicine. The probes are synthetic versions of genes that cause disease. Tossed into a test tube with a small sample of a person’s own genetic material—his DNA—the probes cling to and identify their natural counterparts.
“Raft of Questions.”
Proponents of predictive medicine cite its potentially tremendous benefit in that it will allow, in some instances, people to take preventive measures to ward off certain illnesses. “But it also raises a raft of questions on almost every level—social, psychological, personal, legal and ethical,” says Ms. Wexler, a psychologist who h.
PAGE Running head SCHIZOPHRENIA 1SchizophreniaVernessa.docxkarlhennesey
PAGE
Running head: SCHIZOPHRENIA
1
Schizophrenia
Vernessa Combs
PSY350: Physiological Psychology
December 10, 2019
Schizophrenia
The topic selected was schizophrenia. This is a severe and chronic mental disorder affecting the way humans think, feel and behave. Although this mental disorder is not very common, it has disabling symptoms.
Schizophrenia has continuously been viewed as a disorder that occurs in neurodevelopment. It is associated with a microdeletion syndrome of a chromosome. Neurons migrate to the pial surface from the brain's ventricular zone. "Migration of the neuron cell body is mediated via microtubule-based transport organized by the centrosome. First, the centrosome moves up the microtubule, followed by the nucleus and the cell body” (Pearlson, 2015). Neuronal migrations are reportedly caused by Reelin.
The etiology of schizophrenia is unknown, however, several risk factors have been associated with its development. These include environmental and genetic factors. Genetic factors are, however, insufficient to account for the development of the disease. They must be accompanied by other factors for the disease to develop. "Because the concordance rate for monozygotic twins only approaches 50%, genetic makeup alone is not sufficient for the development of schizophrenia, and non-genetic or sporadic forms of the disorder must exist” (Miyamoto et al, 2013).
Environmental factors that play an important role in the etiology of schizophrenia include obstetric complications such as hypoxia, preeclampsia, and premature birth. Other environmental factors include maternal viral infections and stress occurring in neurodevelopment. Stress during neurodevelopment may be caused by other factors such as microbial infections.
The pathology of schizophrenia includes the transcriptional dysregulation at the cerebral cortex and chromosomal conformations. “Anatomic, neurotransmitter and immune system abnormalities have been implicated in the pathophysiology of schizophrenia” (Miyamoto et al, 2013). Differences have been observed in the brains of people with schizophrenia compared to the brains of people without the disease in neuroimaging studies. The medial temporal areas of the brain have a decreased volume while the ventricles are larger. Structural abnormalities such as volume reductions and ventricular enlargements have been associated with the disease.
The dopaminergic system abnormalities are also associated with schizophrenia. The immune system is also disturbed in people with the disease. “Overactivation of the immune system (eg, from prenatal infection or postnatal stress) may result in overexpression of inflammatory cytokines and subsequent alteration of brain structure and function” (Nuckols et al, 2013). Anatomic abnormalities may also be observed in the hippocampus.
In the prefrontal cortex, there has been a reported increase in neuronal density. One of the areas of the prefrontal cortex, area 9, has been found to h ...
Summary Report: "Mental Health Throughout Life"
Herrenhausen Conference on Mental Illnesses, Hanover, April 3-5, 2013
Mechanisms of vulnerability for mental illnesses over lifetime were the focus of the Volkswagen Foundation’s second Herrenhausen Conference. Concentrating on particularly sensitive and susceptible phases of mental development, renowned experts shared their latest research and insights into risk for and resilience against mental illnesses. Building on this material, in a concluding Session new approaches for improving mental health and treating mental disorders were highlighted.
Folks with schizophrenia may hear voices that are not there. Some may be convinced that other folks are reading their thoughts, controlling how they think, or plotting against them. This can distress patients severely and persistently, making them withdrawn and frantic.
READINGS The following two articles show breathtaking advances.docxcatheryncouper
READINGS
The following two articles show breathtaking advances in the ability to detect whether a person will suffer from a particular genetic disease. The first article contains references to all three types of evidence discussed in this chapter. Compare the language used to depict direct experimentation, after-the-fact evidence, and values questions.
Predictive Probes
by Jerry E. Bishop
Several years ago, Nancy Wexler’s mother died of Huntington’s disease, a hereditary and always-fatal affliction that strikes in midlife. Since then, Ms. Wexler, the 38-year-old president of the Hereditary Diseases Foundation in Santa Monica, Calif., has lived with the uncertainty of whether she, too, inherited the deadly gene.
That uncertainty may soon be resolved. A few months ago, scientists announced they were on the verge of completing a new test to detect the gene for Huntington’s disease (formerly called Huntington’s chorea). But deciding whether to submit herself to the test is an anguishing choice for Ms. Wexler. “If I came out lucky, taking the test would be terrific, of course,” she says. “But if I came out unlucky, well …”
Her dilemma is an extreme example of the kind thousands of Americans will face in the not-too-distant future as scientists learn how to pinpoint genes that cause or predispose a person to a future illness.
The test to detect the Huntington’s disease gene should be ready within one to two years. Researchers already have detected some of the genes that can lead to premature heart attacks and, in the near future, hope to spot those that could predispose a person to breast or colon cancer. Eventually, scientists believe they will be able to detect genes leading to diabetes, depression, schizophrenia and the premature senility called Alzheimer’s disease.
“Extraordinary Power.”
“This new technology has an extraordinary power to predict any disease where there is any kind of genetic influence,” Ms. Wexler says. “Instead of looking in a crystal ball to see your future, you’ll look in your genes.”
Doctors long have been able to crudely predict a person’s future illness. By studying disease patterns, for example, they can say that heavy cigarette smokers have 10 times the risk of developing lung cancer as nonsmokers and that middle-aged men with high blood cholesterol levels have higher-than-normal risk of heart attacks. Geneticists also look at family medical pedigrees to determine the chances of children inheriting any of the 3,000 known genetic disorders.
But such predictions are similar to casino odds. Doctors can’t predict which smokers will actually develop lung cancer, which individual will have a premature heart attack or which child actually inherited a defective gene.
Genetic probes, however, will change predictive medicine. The probes are synthetic versions of genes that cause disease. Tossed into a test tube with a small sample of a person’s own genetic material—his DNA—the probes cling to and identify their n ...
Predictive Probes (Art. 1)by Jerry E. BishopSeveral years .docxChantellPantoja184
Predictive Probes (Art. 1)
by Jerry E. Bishop
Several years ago, Nancy Wexler’s mother died of Huntington’s disease, a hereditary and always-fatal affliction that strikes in midlife. Since then, Ms. Wexler, the 38-year-old president of the Hereditary Diseases Foundation in Santa Monica, Calif., has lived with the uncertainty of whether she, too, inherited the deadly gene.
That uncertainty may soon be resolved. A few months ago, scientists announced they were on the verge of completing a new test to detect the gene for Huntington’s disease (formerly called Huntington’s chorea). But deciding whether to submit herself to the test is an anguishing choice for Ms. Wexler. “If I came out lucky, taking the test would be terrific, of course,” she says. “But if I came out unlucky, well …”
Her dilemma is an extreme example of the kind thousands of Americans will face in the not-too-distant future as scientists learn how to pinpoint genes that cause or predispose a person to a future illness.
The test to detect the Huntington’s disease gene should be ready within one to two years. Researchers already have detected some of the genes that can lead to premature heart attacks and, in the near future, hope to spot those that could predispose a person to breast or colon cancer. Eventually, scientists believe they will be able to detect genes leading to diabetes, depression, schizophrenia and the premature senility called Alzheimer’s disease.
“This new technology has an extraordinary power to predict any disease where there is any kind of genetic influence,” Ms. Wexler says. “Instead of looking in a crystal ball to see your future, you’ll look in your genes.”
Doctors long have been able to crudely predict a person’s future illness. By studying disease patterns, for example, they can say that heavy cigarette smokers have 10 times the risk of developing lung cancer as nonsmokers and that middle-aged men with high blood cholesterol levels have higher-than-normal risk of heart attacks. Geneticists also look at family medical pedigrees to determine the chances of children inheriting any of the 3,000 known genetic disorders.
But such predictions are similar to casino odds. Doctors can’t predict which smokers will actually develop lung cancer, which individual will have a premature heart attack or which child actually inherited a defective gene.
Genetic probes, however, will change predictive medicine. The probes are synthetic versions of genes that cause disease. Tossed into a test tube with a small sample of a person’s own genetic material—his DNA—the probes cling to and identify their natural counterparts.
“Raft of Questions.”
Proponents of predictive medicine cite its potentially tremendous benefit in that it will allow, in some instances, people to take preventive measures to ward off certain illnesses. “But it also raises a raft of questions on almost every level—social, psychological, personal, legal and ethical,” says Ms. Wexler, a psychologist who h.
Biomarkers outperform symptoms in parsing psychosis subgroupsBARRY STANLEY 2 fasd
Identification of Distinct Psychosis Biotypes Using Brain-Based Biomarkers Brett A. Clementz, Ph.D., John A. Sweeney, Ph.D., Jordan P. Hamm, Ph.D., Elena I. Ivleva, M.D., Ph.D., Lauren E. Ethridge, Ph.D., Godfrey D. Pearlson, M.D., Matcheri S. Keshavan, M.D., Carol A. Taming, M.D.
Neuro Quantology is an international, interdisciplinary, open-access, peer-reviewed journal that publishes original research and review articles on the interface between quantum physics and neuroscience. The journal focuses on the exploration of the neural mechanisms underlying consciousness, cognition, perception, and behavior from a quantum perspective. Neuro Quantology is published monthly.
Running head SCHIZOPHRENIA MENTAL DISORDER .docxtoltonkendal
Running head: SCHIZOPHRENIA MENTAL DISORDER 1
SCHIZOPHRENIA MENTAL DISORDER 2
Schizophrenia Mental Disorder
Student’s Name
Course Name
Instructor’s Name
University Affiliation
Schizophrenia Mental Disorder
Introduction
Schizophrenia is a type of psychological illness. It is a chronic and unembellished mental disorder that mainly distresses an individual’s thinking, norms as well as to their extent of sensation. According to modern day research, reports indicates that persons who have schizophrenia might appear as if they have misplaced touch with realism. However, much it is not collective as in comparison with the other mental disorders, its symptoms seem to be much disabling in nature (Miller, 2012). An example is a reduction of a person’s pleasure in their daily undertakings. It raises the question; what can a man do in the absence of desire and affection in all their doings? From the information as already mentioned above, this paper takes turn providing an enhanced analysis of the mental disorder disease – Schizophrenia.
Signs and Symptoms
In close to all the reported cases, signs and symptoms of schizophrenia often start from ages ranging between 16 and 30. There are however fewer cases that the disease has identification among the children. In this paper, it classifies the symptoms and signs into three categories. They include the positive, negative, as well as to the cognitive symptoms as illustrated below.
Positive signs:
In this category, they have a regard for psychotic norms. It means that it is hard to depict the signs commonly in people who are living a healthy lifestyle. However, the given individuals might tend to part ways with their connectivity with different components of reality. The symptoms might include: -
· Delusions
· Agitated movements of the body in a disorderly manner
· Hallucinations
· Unfamiliar perspective of thinking entailing disorderly thoughts and imaginations
Negative symptoms:
In this set, symptoms have a closer affiliation with disturbances to both the common behaviors as well as to particular emotions (Mueser, 2011). The symptoms comprise of: -
· Condensed level of speaking
· Reduction in the extent of both pleasure and feelings in a person’s everyday life undertakings
· Decline on the voice tone as well as the ordinary portrayal of emotions
· Hardships in commencing and sustaining of various activities
Cognitive symptoms:
In this set of symptoms, it varies from one given an individual to the other. To certain people, the symptoms are observable as being delicate in nature. On the other hand, the symptoms prove to be extra severe (Weiberger et al., 2011). In such situations, the affected persons are capable of recognizing alterations in either the facets of thinking and imagination, as well as to variations in their memory. Examples of symptoms ...
Schizophrenia is a group of severe brain disorders in which people interpret reality abnormally. Schizophrenia may result in some combination of hallucinations, delusions, and disordered thinking and behaviour.
Contrary to some popular belief, schizophrenia is not split personality or multiple personality. The word “schizophrenia” does mean “split mind,” but it refers to a disruption of the usual balance of emotions and thinking (Mayo, 2013).
Schizophrenia is a chronic condition, requiring lifelong treatment.
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Biomarkers outperform symptoms in parsing psychosis subgroupsBARRY STANLEY 2 fasd
Identification of Distinct Psychosis Biotypes Using Brain-Based Biomarkers Brett A. Clementz, Ph.D., John A. Sweeney, Ph.D., Jordan P. Hamm, Ph.D., Elena I. Ivleva, M.D., Ph.D., Lauren E. Ethridge, Ph.D., Godfrey D. Pearlson, M.D., Matcheri S. Keshavan, M.D., Carol A. Taming, M.D.
Neuro Quantology is an international, interdisciplinary, open-access, peer-reviewed journal that publishes original research and review articles on the interface between quantum physics and neuroscience. The journal focuses on the exploration of the neural mechanisms underlying consciousness, cognition, perception, and behavior from a quantum perspective. Neuro Quantology is published monthly.
Running head SCHIZOPHRENIA MENTAL DISORDER .docxtoltonkendal
Running head: SCHIZOPHRENIA MENTAL DISORDER 1
SCHIZOPHRENIA MENTAL DISORDER 2
Schizophrenia Mental Disorder
Student’s Name
Course Name
Instructor’s Name
University Affiliation
Schizophrenia Mental Disorder
Introduction
Schizophrenia is a type of psychological illness. It is a chronic and unembellished mental disorder that mainly distresses an individual’s thinking, norms as well as to their extent of sensation. According to modern day research, reports indicates that persons who have schizophrenia might appear as if they have misplaced touch with realism. However, much it is not collective as in comparison with the other mental disorders, its symptoms seem to be much disabling in nature (Miller, 2012). An example is a reduction of a person’s pleasure in their daily undertakings. It raises the question; what can a man do in the absence of desire and affection in all their doings? From the information as already mentioned above, this paper takes turn providing an enhanced analysis of the mental disorder disease – Schizophrenia.
Signs and Symptoms
In close to all the reported cases, signs and symptoms of schizophrenia often start from ages ranging between 16 and 30. There are however fewer cases that the disease has identification among the children. In this paper, it classifies the symptoms and signs into three categories. They include the positive, negative, as well as to the cognitive symptoms as illustrated below.
Positive signs:
In this category, they have a regard for psychotic norms. It means that it is hard to depict the signs commonly in people who are living a healthy lifestyle. However, the given individuals might tend to part ways with their connectivity with different components of reality. The symptoms might include: -
· Delusions
· Agitated movements of the body in a disorderly manner
· Hallucinations
· Unfamiliar perspective of thinking entailing disorderly thoughts and imaginations
Negative symptoms:
In this set, symptoms have a closer affiliation with disturbances to both the common behaviors as well as to particular emotions (Mueser, 2011). The symptoms comprise of: -
· Condensed level of speaking
· Reduction in the extent of both pleasure and feelings in a person’s everyday life undertakings
· Decline on the voice tone as well as the ordinary portrayal of emotions
· Hardships in commencing and sustaining of various activities
Cognitive symptoms:
In this set of symptoms, it varies from one given an individual to the other. To certain people, the symptoms are observable as being delicate in nature. On the other hand, the symptoms prove to be extra severe (Weiberger et al., 2011). In such situations, the affected persons are capable of recognizing alterations in either the facets of thinking and imagination, as well as to variations in their memory. Examples of symptoms ...
Schizophrenia is a group of severe brain disorders in which people interpret reality abnormally. Schizophrenia may result in some combination of hallucinations, delusions, and disordered thinking and behaviour.
Contrary to some popular belief, schizophrenia is not split personality or multiple personality. The word “schizophrenia” does mean “split mind,” but it refers to a disruption of the usual balance of emotions and thinking (Mayo, 2013).
Schizophrenia is a chronic condition, requiring lifelong treatment.
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
1. New Schizophrenia Risk Genes
In a large new study, two newly discovered genes have been
linked to schizophrenia, while a previously known gene
associated with schizophrenia risk has also been linked to
autism.
According to the researchers, the findings expand our
understanding of brain diseases and may lead to new
treatment targets.
This is the first known study to look at the risk of schizophrenia
in different groups of people, particularly those with African
ancestry. It was discovered that rare harmful variations in gene
proteins increase the risk of schizophrenia in people of all
ethnicities.
As with many neurological conditions, the precise causes of
schizophrenia are varied and complex, and remain largely
unknown, though it appears that a combination of genetic,
environmental, and biological changes in the brain play a role.
"The goal of this study was to better understand how rare
genetic variants influence a person's risk of developing severe
mental illness, specifically schizophrenia," says genetic
psychiatrist Alexander Charney of Mount Sinai's Icahn School of
2. Medicine.
Recent research has found that people with schizophrenia have
more rare protein-truncating variants (PTVs) than people who
do not have schizophrenia. PTVs are DNA code changes that
can cause a gene to produce a protein that lacks essential
components, causing it to function incorrectly.
However, that study, like most genetic studies, was conducted
on European populations, despite the fact that schizophrenia is
prevalent globally.
The most recent study discovered two new risk genes, SRRM2
and AKAP11, by comparing the gene sequences of people with
schizophrenia to those of healthy people from various groups,
particularly those of African ancestry.
PCLO, a third gene identified in the study, has previously been
linked to schizophrenia, but it is now known that it also
increases the risk of autism. This adds to our understanding of
the genetic overlap between some neurological conditions.
"It has long been recognised that illnesses share genetic
components. Clinically, genes in the same family may appear
differently. "The same variant in the same family may cause
autism in one member and schizophrenia in another," says
Charney.
The idea of the same gene having different manifestations is
3. very intriguing to us because it could be useful in treating
people in the clinic."
To reach their conclusions, the researchers used a
meta-analysis that included 35,828 cases and 107,877 controls
from previously published datasets.
A meta-analysis can help researchers identify patterns or
inconsistencies in the findings of different studies and provide a
more accurate estimate of the effect size by pooling data from
multiple studies that have investigated the same phenomenon.
Because sequencing the entire genome is expensive, the
researchers used targeted gene sequencing on carefully
selected genes from this data - from 11,580 people with
schizophrenia or schizoaffective disorders and 10,555 people
with no known diagnosis of psychiatric disorder. The
people whose genes were used in the study were not related,
and 40% were non-Europeans.
"By focusing on a subset of genes, we discovered rare damaging
variants that could potentially lead to new medicines for
schizophrenia," says lead author Dongjing Liu of Mount Sinai's
Icahn School of Medicine.
"Also significant: we discovered that rare damaging variants in
evolutionarily constrained genes confer a similar magnitude of
schizophrenia risk among those different populations, and that
4. genetic factors previously established in predominantly white
people for this debilitating disease have now been extended to
non-whites."
Schizophrenia is a severe mental illness that has an impact on
one's thinking, feelings, and behaviour. According to statistics,
it shortens a person's life by nearly 15 years, usually beginning
in late adolescence or early adulthood and affecting
approximately 7 in 1,000 people.
Hearing or seeing things that aren't there, believing in things
that aren't real, disorganised thinking and behaviour, and a lack
of motivation are all symptoms. The symptoms can be very
upsetting for both the person experiencing them and those
around them.
Many people with schizophrenia benefit from treatment, but
current medications do not work for everyone, symptoms and
side effects vary, and more research is required.
The researchers intend to conduct additional research into the
clinical implications of these newly discovered genes on specific
schizophrenia symptoms or behaviours, as well as identify
potential medications to target them.
According to Liu and colleagues, the most important
contribution of this study to the field of genetics is
demonstrating that genetic risk is consistent across ethnicities.
5. "Achieving diversity in human genetic research must be a top
priority to avoid worsening health disparities as genetic
research findings begin to be translated into clinical practise,"
they write.
This appears to be a positive step in the right direction.
The study was peer-reviewed and published in the journal
Nature Genetics.
WATCH THESE VIDEOS:
https://uii.io/F8m3
https://uii.io/tolfpHiF
https://uii.io/ZvQCRfMSRW
